Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents

Phase 3

Completed

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Other standard therapy for ADHD
Drug: Atomoxetine

First Posted Date: 2007-03-14

Last Posted Date: 2010-04-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 399

Registration Number: NCT00447278

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, South Yorkshire, United Kingdom

A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

Phase 1

Terminated

Conditions: Small Cell Lung Cancer
Carcinoma, Small Cell
SCLC

Interventions: Drug: pemetrexed
Drug: cisplatin
Radiation: radiation

First Posted Date: 2007-03-14

Last Posted Date: 2009-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 9

Registration Number: NCT00447421

Locations: 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands

Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.

Interventions: Drug: Pemetrexed
Drug: Erlotinib

First Posted Date: 2007-03-13

Last Posted Date: 2011-10-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 204

Registration Number: NCT00447057

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden

Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease

Phase 4

Completed

Conditions: Major Depressive Disorder
Idiopathic Parkinson Disease

Interventions: Drug: Duloxetine hydrochloride

First Posted Date: 2007-02-19

Last Posted Date: 2010-09-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 151

Registration Number: NCT00437125

Locations: 🇮🇹
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy

Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Human Insulin Inhalation Powder
Drug: Insulin Glargine

First Posted Date: 2007-02-19

Last Posted Date: 2018-03-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 142

Registration Number: NCT00437112

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sabadell, Spain

Chemotherapy for Participants With Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Large Cell, Diffuse

Interventions: Drug: enzastaurin
Drug: gemcitabine
Drug: rituximab
Drug: oxaliplatin

First Posted Date: 2007-02-19

Last Posted Date: 2020-08-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 68

Registration Number: NCT00436280

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation

Enzastaurin in Combination of Capecitabine to Treat Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: placebo
Drug: enzastaurin
Drug: capecitabine

First Posted Date: 2007-02-19

Last Posted Date: 2020-08-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 86

Registration Number: NCT00437294

Locations: 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durban, South Africa

A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Carcinoma
Colorectal Tumor
Colorectal Cancer

Interventions: Drug: enzastaurin
Drug: cetuximab
Drug: irinotecan

First Posted Date: 2007-02-19

Last Posted Date: 2020-07-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT00437268

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, United States

Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain

Phase 3

Completed

Conditions: Osteoarthritis Knee Pain

Interventions: Drug: Duloxetine
Drug: Placebo

First Posted Date: 2007-02-09

Last Posted Date: 2009-09-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 256

Registration Number: NCT00433290

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gothenburg, Sweden

Phase 3 Clinical Trial of Teriparatide in Japan

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Teriparatide
Drug: Placebo

First Posted Date: 2007-02-09

Last Posted Date: 2010-09-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 207

Registration Number: NCT00433160

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tottori, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy